Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Hydrix has secured exclusive rights to distribute Angel Medical Systems’ Guardian System in eight Asia Pacific countries
  • The Guardian System is the world’s first FDA-approved implantable heart attack alerting device
  • This services deal marks the second between Hydrix and AngelMed after an initial partnership signed in July 2019 to update the Guardian System
  • The Asia Pacific countries include but are not limited to Singapore, Japan, Hong Kong, and Australia

Hydrix has secured exclusive rights to distribute Angel Medical Systems’ Guardian System in eight Asia Pacific countries.

The Guardian System is the world’s first FDA-approved implantable heart attack alerting device.

It includes a cardiac monitoring and alerting device that is implanted like a pacemaker. However, unlike a pacemaker, the Guardian monitors your heart’s electric signal 24 hours a day.

The Guardian System has been proven to alert patients to seek immediate medical attention due to an impending Acute Coronary Syndrome (ACS) event caused by a blockage of blood flow and oxygen to the heart.

This services deal marks the second between Hydrix and AngelMed. On July 30 2019, Hydrix announced entering a contract with AngelMed to provide product design, engineering, and regulatory consulting services for the updating of the Guardian System.

“We are delighted to expand our commercial arrangements with Hydrix. Their regulatory and product engineering track record working with innovative global medical device companies, combined with their market knowledge, makes them an excellent strategic partner for AngelMed,” AngelMed CEO Dr David Fischell said.

In addition to the exclusive distribution deal, Hydrix will make a US$500,000 strategic equity investment in AngelMed which will see the company own 2.6 per cent of AngelMed’s share capital.

“The investment and exclusive distribution arrangements are consistent with our buy-build-invest strategy and a natural extension to our consulting services contract. This partnership represents an endorsement of Hydrix’ value proposition to support companies commercialising innovative medical devices,” Hydrix Chairman Gavin Coote said.

Once the transaction is completed, Hydrix will be appointed exclusive distributor of the Guardian System across eight Asia Pacific countries. These include Australia, Japan, Singapore and Hong Kong.

HYD by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.